KRAS and non-small cell lung carcinoma: In summary, while small-molecule inhibitors ofKRASG12Chave demonstrated clinical efficacy across solid malignancies and led to regulatory approval for the treatment of NSCLC, there is still an unmet need to develop new strategies to target KRAS that overcomeKRASG12C “off” resistance on the one hand and target other common KRAS mutations seen across different malignancies and for whom no approved KRAS inhibitors are currently available on the other hand.